AbbVie signs a global licensing deal with Haisco Pharmaceutical for a multi-asset pain pipeline, including preclinical to Phase 1 compounds, with $30 million upfront and up to $715 million in milestones plus royalties
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Haisco Pharmaceutical Group Co., Ltd. has entered an exclusive licensing agreement with AbbVie to advance a portfolio of novel pain therapies outside mainland China, Hong Kong, and Macau. The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize multiple compounds targeting pain-related indications, with programs currently spanning preclinical to Phase 1 clinical development in China.
The collaboration gives AbbVie access to a multi-asset pipeline designed to address unmet needs in pain management, while allowing Haisco to expand its international footprint. AbbVie will leverage its global development infrastructure and neuroscience expertise to advance the candidates beyond early-stage clinical testing and toward worldwide commercialization.
Haisco Chief Executive Officer Dr. Pangke Yan said the partnership aligns with the company’s international strategy and is expected to create long-term value. He noted that collaborating with a global biopharmaceutical leader such as AbbVie could accelerate development of innovative pain therapies and help deliver new treatment options to patients worldwide.
Under the terms of the agreement, Haisco will receive an upfront payment of $30 million and is eligible for up to $715 million in development, regulatory, and commercial milestone payments. The company is also entitled to tiered royalties on future global net sales.
Reference
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain, 13 April 2026, https://www.prnewswire.com/news-releases/haisco-enters-into-exclusive-license-agreement-with-abbvie-to-develop-novel-medicines-for-pain-302740226.html
About the Writer
Chikkula Pavan Kumar, PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.
